Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-097923
Filing Date
2025-10-08
Accepted
2025-10-08 16:15:29
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 22493
2 EXHIBIT 99.1 tm2528312d1_ex99-1.htm EX-99.1 11249
  Complete submission text file 0001104659-25-097923.txt   35609
Mailing Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 23, SUITE 105 WALTHAM MA 02453 (781) 312-3013
Jade Biosciences, Inc. (Subject) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92668 | Film No.: 251382478
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428
Business Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 267-262-5300
Fairmount Funds Management LLC (Filed by) CIK: 0001802528 (see all company filings)

EIN.: 364841215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A